Aditxt, Inc. reported acute liquidity constraints with cash reserves under $270,000 and a current ratio of 0.06 as of Q1 2026, compounded by over $5.8 million in accounts payable past due by more than 90 days. The company faces significant default risk and potential asset foreclosure under secured creditor agreements. Despite these financial pressures, Aditxt’s lead immunotherapy candidate, ADI-100, advanced into human clinical trials in early 2026, marking a key milestone. The firm’s biotechnology business model remains heavily reliant on continued capital raises, regulatory approvals, and patent license maintenance amid intense competition and Nasdaq delisting threats.